1-18 of 18
Alexia Iasonos
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase II Study of Fulvestrant plus Abemaciclib in Hormone Receptor-Positive Advanced or Recurrent Endometrial Cancer

Angela K. Green, Qin Zhou, Alexia Iasonos, William A. Zammarrelli, Britta Weigelt, Lora H. Ellenson, Rashmi Chhetri-Long, Pooja Shah, Jade Loh, Vania Hom, Pier Selenica, Joseph Erinjeri, Iva Petkovska, Sarat Chandarlapaty, Seth Cohen, Rachel Grisham, Jason Konner, Maria M. Rubinstein, William Tew, Tiffany Troso-Sandoval, Carol Aghajanian, Vicky Makker
Journal: Clinical Cancer Research
Clin Cancer Res (2024)
https://doi.org/10.1158/1078-0432.CCR-24-1999
Published: 19 November 2024
View article titled, A Phase II Study of Fulvestrant plus Abemaciclib in Hormone Receptor-Positive Advanced or Recurrent Endometrial Cancer
Open the PDF for A Phase II Study of Fulvestrant plus Abemaciclib in Hormone Receptor-Positive Advanced or Recurrent Endometrial Cancer in another window
Includes: Supplementary data
Journal Articles

Assessing the Genomic Landscape of Cervical Cancers: Clinical Opportunities and Therapeutic Targets

Claire F. Friedman, Vignesh Ravichandran, Kathryn Miller, Chad Vanderbilt, Qin Zhou, Alexia Iasonos, Malavika Vivek, Pamela Mishra, Mario M. Leitao, Jr, Vance Broach, Yukio Sonoda, Chrisann Kyi, Dmitriy Zamarin, Roisin E. O'Cearbhaill, Jason Konner, Michael F. Berger, Britta Weigelt, Amir Momeni Boroujeni, Kay J. Park, Carol Aghajanian, David B. Solit, Mark T.A. Donoghue
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (22): 4660–4668.
https://doi.org/10.1158/1078-0432.CCR-23-1078
Published: 14 November 2023
View article titled, Assessing the Genomic Landscape of Cervical Cancers: Clinical Opportunities and Therapeutic Targets
Open the PDF for Assessing the Genomic Landscape of Cervical Cancers: Clinical Opportunities and Therapeutic Targets in another window
Includes: Supplementary data
Journal Articles

High-Sensitivity Mutation Analysis of Cell-Free DNA for Disease Monitoring in Endometrial Cancer

Charles W. Ashley, Pier Selenica, Juber Patel, Michelle Wu, Josip Nincevic, Yulia Lakhman, Qin Zhou, Ronak H. Shah, Michael F. Berger, Arnaud Da Cruz Paula, David N. Brown, Antonio Marra, Alexia Iasonos, Amir Momeni-Boroujeni, Kaled M. Alektiar, Kara Long Roche, Oliver Zivanovic, Jennifer J. Mueller, Dmitriy Zamarin, Vance A. Broach, Yukio Sonoda, Mario M. Leitao, Jr, Claire F. Friedman, Elizabeth Jewell, Jorge S. Reis-Filho, Lora H. Ellenson, Carol Aghajanian, Nadeem R. Abu-Rustum, Karen Cadoo, Britta Weigelt
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (2): 410–421.
https://doi.org/10.1158/1078-0432.CCR-22-1134
Published: 17 January 2023
View article titled, High-Sensitivity Mutation Analysis of Cell-Free DNA for Disease Monitoring in Endometrial Cancer
Open the PDF for High-Sensitivity Mutation Analysis of Cell-Free DNA for Disease Monitoring in Endometrial Cancer in another window
Includes: Supplementary data
Journal Articles

MAPK Pathway Genetic Alterations Are Associated with Prolonged Overall Survival in Low-Grade Serous Ovarian Carcinoma

Beryl Manning-Geist, Sushmita Gordhandas, Ying L. Liu, Qin Zhou, Alexia Iasonos, Arnaud Da Cruz Paula, Diana Mandelker, Kara Long Roche, Oliver Zivanovic, Anna Maio, Yelena Kemel, Dennis S. Chi, Roisin E. O'Cearbhaill, Carol Aghajanian, Britta Weigelt, M. Herman Chui, Rachel N. Grisham
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (20): 4456–4465.
https://doi.org/10.1158/1078-0432.CCR-21-4183
Published: 14 October 2022
View article titled, MAPK Pathway Genetic Alterations Are Associated with Prolonged Overall Survival in Low-Grade Serous Ovarian Carcinoma
Open the PDF for MAPK Pathway Genetic Alterations Are Associated with Prolonged Overall Survival in Low-Grade Serous Ovarian Carcinoma in another window
Includes: Supplementary data
Journal Articles

Microsatellite Instability–High Endometrial Cancers with MLH1 Promoter Hypermethylation Have Distinct Molecular and Clinical Profiles

Beryl L. Manning-Geist, Ying L. Liu, Kelly A. Devereaux, Arnaud Da Cruz Paula, Qin C. Zhou, Weining Ma, Pier Selenica, Ozge Ceyhan-Birsoy, Lea A. Moukarzel, Timothy Hoang, Sushmita Gordhandas, Maria M. Rubinstein, Claire F. Friedman, Carol Aghajanian, Nadeem R. Abu-Rustum, Zsofia K. Stadler, Jorge S. Reis-Filho, Alexia Iasonos, Dmitriy Zamarin, Lora H. Ellenson, Yulia Lakhman, Diana L. Mandelker, Britta Weigelt
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (19): 4302–4311.
https://doi.org/10.1158/1078-0432.CCR-22-0713
Published: 03 October 2022
View article titled, Microsatellite Instability–High Endometrial Cancers with <em>MLH1</em> Promoter Hypermethylation Have Distinct Molecular and Clinical Profiles
Open the PDF for Microsatellite Instability–High Endometrial Cancers with <em>MLH1</em> Promoter Hypermethylation Have Distinct Molecular and Clinical Profiles in another window
Includes: Supplementary data
Journal Articles

A Phase I Study of Alpelisib in Combination with Trastuzumab and LJM716 in Patients with PIK3CA-Mutated HER2-Positive Metastatic Breast Cancer

Komal Jhaveri, Joshua Z. Drago, Payal Deepak Shah, Rui Wang, Fresia Pareja, Fanni Ratzon, Alexia Iasonos, Sujata Patil, Neal Rosen, Monica N. Fornier, Nancy T. Sklarin, Sarat Chandarlapaty, Shanu Modi
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (14): 3867–3875.
https://doi.org/10.1158/1078-0432.CCR-21-0047
Published: 15 July 2021
View article titled, A Phase I Study of Alpelisib in Combination with Trastuzumab and LJM716 in Patients with <em>PIK3CA</em>-Mutated HER2-Positive Metastatic Breast Cancer
Open the PDF for A Phase I Study of Alpelisib in Combination with Trastuzumab and LJM716 in Patients with <em>PIK3CA</em>-Mutated HER2-Positive Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract 16: Landscape and outcome of TRK fusion-positive Cancers

Ezra Y. Rosen, Debra A. Goldman, Jaclyn F. Hechtman, Ryma Benayed, Alison M. Schram, Emiliano Cocco, Sophie Shifman, Yixiao Gong, Ritika Kundra, James P. Solomon, Alberto Bardelli, Maurizio Scaltriti, Alexander Drilon, Alexia Iasonos, Barry S. Taylor, David M. Hyman
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (12_Supplement_1): 16.
https://doi.org/10.1158/1557-3265.ADVPRECMED20-16
Published: 15 June 2020
View article titled, Abstract 16: Landscape and outcome of TRK fusion-positive Cancers
Journal Articles

TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations

Ezra Y. Rosen, Debra A. Goldman, Jaclyn F. Hechtman, Ryma Benayed, Alison M. Schram, Emiliano Cocco, Sophie Shifman, Yixiao Gong, Ritika Kundra, James P. Solomon, Alberto Bardelli, Maurizio Scaltriti, Alexander Drilon, Alexia Iasonos, Barry S. Taylor, David M. Hyman
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (7): 1624–1632.
https://doi.org/10.1158/1078-0432.CCR-19-3165
Published: 01 April 2020
View article titled, TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations
Open the PDF for TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations in another window
Includes: Supplementary data
Journal Articles

Report of the 14th International Conference on Malignant Lymphoma (ICML) Closed Workshop on Future Design of Clinical Trials in Lymphomas

Anastasios Stathis, Alexia Iasonos, John F. Seymour, Catherine Thieblemont, Vincent Ribrag, Emanuele Zucca, Anas Younes
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (13): 2993–2998.
https://doi.org/10.1158/1078-0432.CCR-17-3021
Published: 01 July 2018
View article titled, Report of the 14th International Conference on Malignant Lymphoma (ICML) Closed Workshop on Future Design of Clinical Trials in Lymphomas
Open the PDF for Report of the 14th International Conference on Malignant Lymphoma (ICML) Closed Workshop on Future Design of Clinical Trials in Lymphomas in another window
Journal Articles

Quantifying Treatment Benefit in Molecular Subgroups to Assess a Predictive Biomarker

Alexia Iasonos, Paul B. Chapman, Jaya M. Satagopan
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (9): 2114–2120.
https://doi.org/10.1158/1078-0432.CCR-15-2517
Published: 01 May 2016
View article titled, Quantifying Treatment Benefit in Molecular Subgroups to Assess a Predictive Biomarker
Open the PDF for Quantifying Treatment Benefit in Molecular Subgroups to Assess a Predictive Biomarker in another window
Includes: Supplementary data
Journal Articles

Measuring Toxicity in Phase I Clinical Trials—Letter

David M. Hyman, Anne Eaton, S. Percy Ivy, David R. Spriggs, Alexia Iasonos
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (7): 1828.
https://doi.org/10.1158/1078-0432.CCR-15-3043
Published: 31 March 2016
View article titled, Measuring Toxicity in Phase I Clinical Trials—Letter
Open the PDF for Measuring Toxicity in Phase I Clinical Trials—Letter in another window
Journal Articles

Toxicity Attribution in Phase I Trials: Evaluating the Effect of Dose on the Frequency of Related and Unrelated Toxicities

Anne Eaton, Alexia Iasonos, Mrinal M. Gounder, Erika G. Pamer, Alexander Drilon, Diana Vulih, Gary L. Smith, S. Percy Ivy, David R. Spriggs, David M. Hyman
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (3): 553–559.
https://doi.org/10.1158/1078-0432.CCR-15-0339
Published: 31 January 2016
View article titled, Toxicity Attribution in Phase I Trials: Evaluating the Effect of Dose on the Frequency of Related and Unrelated Toxicities
Open the PDF for Toxicity Attribution in Phase I Trials: Evaluating the Effect of Dose on the Frequency of Related and Unrelated Toxicities in another window
Includes: Supplementary data
Journal Articles

The Impact of Non–Drug-Related Toxicities on the Estimation of the Maximum Tolerated Dose in Phase I Trials

Alexia Iasonos, Mrinal Gounder, David R. Spriggs, John F. Gerecitano, David M. Hyman, Sarah Zohar, John O'Quigley
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (19): 5179–5187.
https://doi.org/10.1158/1078-0432.CCR-12-0726
Published: 30 September 2012
View article titled, The Impact of Non–Drug-Related Toxicities on the Estimation of the Maximum Tolerated Dose in Phase I Trials
Open the PDF for The Impact of Non–Drug-Related Toxicities on the Estimation of the Maximum Tolerated Dose in Phase I Trials in another window
Includes: Supplementary data
Journal Articles

Phase I Trial of Weekly and Twice-Weekly Bortezomib with Rituximab, Cyclophosphamide, and Prednisone in Relapsed or Refractory Non–Hodgkin Lymphoma

John Gerecitano, Carol Portlock, Paul Hamlin, Craig H. Moskowitz, Ariela Noy, David Straus, Philip Schulman, Otilia Dumitrescu, Debra Sarasohn, Jennifer Pappanicholaou, Alexia Iasonos, Zhigang Zhang, Qianxing Mo, Endri Horanlli, Celeste N. Rojas, Andrew D. Zelenetz, Owen A. O'Connor
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (8): 2493–2501.
https://doi.org/10.1158/1078-0432.CCR-10-1498
Published: 14 April 2011
View article titled, Phase I Trial of Weekly and Twice-Weekly Bortezomib with Rituximab, Cyclophosphamide, and Prednisone in Relapsed or Refractory Non–Hodgkin Lymphoma
Open the PDF for Phase I Trial of Weekly and Twice-Weekly Bortezomib with Rituximab, Cyclophosphamide, and Prednisone in Relapsed or Refractory Non–Hodgkin Lymphoma in another window
Journal Articles

Epithelial Membrane Protein-2 Is a Novel Therapeutic Target in Ovarian Cancer

Maoyong Fu, Erin L. Maresh, Robert A. Soslow, Mohammad Alavi, Vei Mah, Qin Zhou, Alexia Iasonos, Lee Goodglick, Lynn K. Gordon, Jonathan Braun, Madhuri Wadehra
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (15): 3954–3963.
https://doi.org/10.1158/1078-0432.CCR-10-0368
Published: 28 July 2010
View article titled, Epithelial Membrane Protein-2 Is a Novel Therapeutic Target in Ovarian Cancer
Open the PDF for Epithelial Membrane Protein-2 Is a Novel Therapeutic Target in Ovarian Cancer in another window
Journal Articles

Safety and Immunogenicity Study of NY-ESO-1b Peptide and Montanide ISA-51 Vaccination of Patients with Epithelial Ovarian Cancer in High-Risk First Remission

Catherine S.M. Diefenbach, Sacha Gnjatic, Paul Sabbatini, Carol Aghajanian, Martee L. Hensley, David R. Spriggs, Alexia Iasonos, Helen Lee, Bo Dupont, Sandra Pezzulli, Achim A. Jungbluth, Lloyd J. Old, Jakob Dupont
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (9): 2740–2748.
https://doi.org/10.1158/1078-0432.CCR-07-4619
Published: 01 May 2008
View article titled, Safety and Immunogenicity Study of NY-ESO-1b Peptide and Montanide ISA-51 Vaccination of Patients with Epithelial Ovarian Cancer in High-Risk First Remission
Open the PDF for Safety and Immunogenicity Study of NY-ESO-1b Peptide and Montanide ISA-51 Vaccination of Patients with Epithelial Ovarian Cancer in High-Risk First Remission in another window
Journal Articles

Pilot Study of a Heptavalent Vaccine-Keyhole Limpet Hemocyanin Conjugate plus QS21 in Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

Paul J. Sabbatini, Govind Ragupathi, Chandra Hood, Carol A. Aghajanian, Margrit Juretzka, Alexia Iasonos, Martee L. Hensley, Maria K. Spassova, Ouathek Ouerfelli, David R. Spriggs, William P. Tew, Jason Konner, Henrik Clausen, Nadeem Abu Rustum, Samuel J. Dansihefsky, Philip O. Livingston
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (14): 4170–4177.
https://doi.org/10.1158/1078-0432.CCR-06-2949
Published: 18 July 2007
View article titled, Pilot Study of a Heptavalent Vaccine-Keyhole Limpet Hemocyanin Conjugate plus QS21 in Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
Open the PDF for Pilot Study of a Heptavalent Vaccine-Keyhole Limpet Hemocyanin Conjugate plus QS21 in Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in another window
Journal Articles

Phase I Study of Abagovomab in Patients with Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Paul Sabbatini, Jakob Dupont, Carol Aghajanian, Felicia Derosa, Elizabeth Poynor, Sybil Anderson, Martee Hensley, Phillip Livingston, Alexia Iasonos, David Spriggs, William McGuire, Silke Reinartz, Sally Schneider, Cathy Grande, Shashikant Lele, Kerry Rodabaugh, James Kepner, Soldano Ferrone, Kunle Odunsi
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (18): 5503–5510.
https://doi.org/10.1158/1078-0432.CCR-05-2670
Published: 25 September 2006
View article titled, Phase I Study of Abagovomab in Patients with Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Open the PDF for Phase I Study of Abagovomab in Patients with Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in another window